CTLA4 and neoplasm: Of note, the IL2 cytokine and the IL2-modified version have been described as being able to synergize with anti-CTLA4 and anti-PD1/PDL-1 antibodies in terms of tumor control, but only a combination of the IL2-based cytokine with CTLA4 is able to re-activate NK cells in vivo [83].